TARS — Tarsus Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $3.47bn
- $3.09bn
- $451.36m
Tarsus Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary
Brief: Tarsus Reports Third Quarter 2022 Financial Results
Tarsus Pharmaceuticals Inc expected to post a loss of 97 cents a share - Earnings Preview
Brief: Tarsus To Present Additional Saturn-2 Pivotal Phase 3 Trial Data At The American Academy Of Optometry 2022 Annual Meeting
Brief: Tarsus Pharmaceuticals Expanded Size Of Board From Eight To Nine Directors
Brief: Tarsus Announces Transition Plans For Board Of Directors
Brief: Tarsus Submits New Drug Application To The FDA For Tp-03 For The Treatment Of Demodex Blepharitis
Brief: Tarsus Pharmaceuticals Reports Qtrly Loss Per Share $0.24
Tarsus Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Brief: Tarsus Pharmaceuticals Initiates Phase 2A Ersa Trial Evaluating Tp-03 For The Treatment Of Meibomian Gland Disease
Tarsus Pharmaceuticals Inc expected to post a loss of 65 cents a share - Earnings Preview
Tarsus Pharmaceuticals Inc expected to post a loss of 92 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Incyte Corp, Atkore Inc, Franklin Resources
U.S. STOCKS ON THE MOVE-Cummins Inc, Hasbro Inc, IonQ Inc
Tarsus Pharma prices upsized equity offering after shares tumble
Brief: Tarsus Announces Pricing Of Upsized $75.6 Mln Public Offering Of Common Stock
Brief: Tarsus Announces Positive Topline Data From Saturn-2 Phase 3, Second Pivotal Trial Of Tp-03 For Treatment Of Demodex Blepharitis
Brief: Tarsus Pharmaceuticals Inc Reports Full-Year 2021 Financial Results
Brief: Tarsus Completes Enrollment For Phase 3 Saturn-2 Trial Of TP-03